• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • COVID-19

    Why the UK wants a new coronavirus test to be made in Senegal

    A prototype of the rapid diagnostic test is just weeks away, and it will be available at cost in Africa, the developers tell Devex.

    By William Worley // 17 March 2020
    An aid worker holds a hand sanitizer in front of a university entrance in Dakar, Senegal. Photo by: REUTERS / Zohra Bensemra

    LONDON — U.K. aid is funding the effort to develop a rapid diagnostic test for COVID-19, which will be jointly manufactured in the United Kingdom and Senegal — a first for the African continent.

    The developers told Devex they intend to sell the tests at cost, making them as affordable as possible, and that producing them in Senegal will make it cheaper and quicker to distribute them across Africa.

    More on COVID-19:

    ► There's a new fund for COVID-19. Here's what you need to know.

    ► Will the private sector unite to fight COVID-19?

    ► Conference call: Preparing Africa for a coronavirus spread — the role of NGOs

    “Ensuring access upfront to diagnostics is critical, especially for outbreak-prone epidemics,” said Joe Fitchett, medical director at Mologic, the U.K. company designing the kits. “By manufacturing in Africa there is an opportunity to ensure production is driven by demand and health need, rather than commercial return.”

    While the pandemic has so far mostly affected the global north, there are widespread fears of the damage it could cause in lower-income countries.

    “We made it very clear to the [British] prime minister … that this test will be made available at cost to low-income settings. No questions asked.”

    — Joe Fitchett, medical director, Mologic

    Current testing for COVID-19 requires laboratories, which are few and far between in low-income countries, and are not keeping up with demand even in better-resourced countries. The hope is that quick, easy-to-use diagnostic tests made in Senegal could ease the burden on local health systems if the outbreak on the continent worsens.

    A prototype of the simple new testing system, which should give a diagnosis of COVID-19 within minutes as opposed to days, is said to be just weeks away from completion.

    The test is being developed by Mologic, funded with £1 million ($1.2 million) from the U.K. government, and will be made in parallel with DiaTropix, an infectious disease testing facility founded by the Institut Pasteur of Dakar, in the Senegalese capital.

    “Everything we do is as simple as possible,” Fitchett said. He told Devex the diagnostic kit will have two components: a saliva test and a low-volume blood test.

    “It's a 10-minute test, it doesn’t need a lab or complex infrastructure, and the most important thing we are doing now upfront is designing this so it could be a self-test,” meaning you could use it anywhere, Fitchett said. “That gives us full flexibility, though we expect clinicians and nurses to be the ones using it first.”

    Mologic’s co-founder, professor Paul Davis, was one of the inventors of the first home pregnancy test. The company’s main purpose is to manufacture affordable tests for neglected tropical diseases. The COVID-19 diagnostic test builds on Mologic’s biotechnology work in this field.

    It should be available at cost in the U.K. and abroad. “We're aiming for less than £1 [per test],” Fitchett said. “We made it very clear to the [British] prime minister on Friday [on an official visit to the laboratory] that this test will be made available at cost to low-income settings. No questions asked.”

    But the challenge for Mologic is not price — it will be producing enough tests to meet immediate and heavy demand. “We’re looking to acquire new manufacturing facilities in the U.K. and boosting our manufacturing capability in the interim,” Fitchett explained. “What we are doing is jointly manufacturing in Africa, in Senegal. That is the first time anyone has done that for an epidemic, let alone a fully regulated rapid test for diagnostics.”

    DiaTropix is a new venture directed by Amadou Sall, a virologist at the Institut Pasteur of Dakar who previously directed the World Health Organization’s Collaborating Center for Arboviruses and Viral Haemorrhagic Fevers.

    Like Mologic, DiaTropix works to provide testing for underserved diseases endemic in Africa, such as dengue. Its funders include the Mérieux Foundation, the Foundation for Innovative New Diagnostics, and the Institut de Recherche pour le Développement, a French public research institute.

    Its staff have already undergone training with Mologic. Other issues remain before manufacturing can take off in Senegal, such as equipment validation and regulation of product batches, but Fitchett was confident the process would run smoothly.

    Cheikh Tidiane Diagne, who manages the program at DiaTropix, said he isn’t anticipating any major challenges. “We are engaging with them [Mologic] from the beginning of the manufacturing … They are transferring standard operating procedures, and our regulatory team is working with them so we can see how to get the tests approved,” he said.

    A “mirroring manufacturing” process with Mologic will see DiaTropix performing the same process at the same time, to begin producing prototypes in mid-April, Diagne said.

    The project was welcomed by Prashant Yadav, visiting fellow at the Center for Global Development and an expert on global health supply chains.

    “Building very long supply chains for testing has its own set of challenges, often economic and how quickly can you respond. So having shorter supply chains is useful and if they can do this in Senegal for Africa and [in the] U.K. for Europe, that would be my textbook ideal model of how to run a supply chain,” he said.

    He added that the success of such a project in practice was largely dependent on having reliable infrastructure, such as an uninterrupted energy supply, and sufficient working capital. Development finance institutions could play a role in ensuring that the DiaTropix facility — and others like it — could stay properly financed.

    • Global Health
    • Private Sector
    • Trade & Policy
    • Mologic
    • DiaTropix
    • United Kingdom
    • Senegal
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • William Worley

      William Worley@willrworley

      Will Worley is the Climate Correspondent for Devex, covering the intersection of development and climate change. He previously worked as UK Correspondent, reporting on the FCDO and British aid policy during a time of seismic reforms. Will’s extensive reporting on the UK aid cuts saw him shortlisted for ‘Specialist Journalist of the Year’ in 2021 by the British Journalism Awards. He can be reached at william.worley@devex.com.

    Search for articles

    Related Stories

    Global healthNew partnerships aim to fix Africa's broken medical supply chains

    New partnerships aim to fix Africa's broken medical supply chains

    78th World Health AssemblyA new model for funding global health takes shape

    A new model for funding global health takes shape

    EnergyOne year in, Mission 300 tests what it takes to power Africa

    One year in, Mission 300 tests what it takes to power Africa

    Pandemic preparednessCountries reach historic pandemic treaty deal after prolonged stalemate

    Countries reach historic pandemic treaty deal after prolonged stalemate

    Most Read

    • 1
      How low-emissions livestock are transforming dairy farming in Africa
    • 2
      Opinion: Mobile credit, savings, and insurance can drive financial health
    • 3
      Opinion: India’s bold leadership in turning the tide for TB
    • 4
      The UN's changing of the guard
    • 5
      USAID's humanitarian bureau is under pressure and overstretched
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement